November 6th, 2018 – Xstrahl Medical and Electronica Y Medicina, S.A. (EYMSA) are announcing a partnership to supply next generation superficial radiotherapy systems for the treatment of non-melanoma skin cancers. “The ability to supply much needed radiotherapy...
Combined radiotherapy and hyperthermia offer great potential for the successful treatment of radio-resistant tumours through thermo-radiosensitization. Tumour response heterogeneity, due to intrinsic, or micro-environmentally induced factors, may greatly influence...
OBJECTIVE: Modern image-guided small animal irradiators like the Xstrahl Small Animal Radiation Research Platform (SARRP) are designed with ultrathin 0.15 mm Cu filters, which compared with more heavily filtrated traditional cabinet-style biological irradiators,...
PURPOSE: To evaluate the acute changes in leukocyte populations after focal irradiation and to assess the role of Interleukin-6 (IL6) in acute and late radiation injury. METHODS AND MATERIALS: Mice were surgically implanted with a radiopaque marker on the surface of...
OBJECTIVES: Small animal radiotherapy research platforms such as XStrahl's SARRP enable more precise irradiation of tumours and normal tissues in preclinical models of cancer. Using an orthotopic G7 glioblastoma (GBM) xenograft model we studied the impact of four...
BACKGROUND: Craniospinal irradiation (CSI) is a crucial component of treatment for medulloblastoma (MB), a brain tumor clinically stratified into prognostically distinct molecular subgroups. Preclinical models of clinically-relevant CSI offer the potential to study...
Xstrahl attended the 59th Annual Meeting of the American Society for Radiation Oncology (ASTRO) conference in San Diego, this September, the world's largest meeting for the radiation oncology community. Over a fantastic four days Xstrahl Life Sciences and Medical...
October 30th, 2018 – Xstrahl Medical, global leaders in superficial radiotherapy devices and advanced radiation research systems, has appointed Neil Madle as Commercial Director - Radiotherapy. Based at Xstrahl’s UK head office in Surrey, Madle will be responsible for...
Xstrahl Medical, global leaders in superficial radiotherapy devices and advanced radiation research systems, has appointed Neil Madle as Commercial Director - Radiotherapy. Based at Xstrahl’s UK head office in Surrey, Madle will be responsible for the commercial...